BRAS DDP trains

drug development physicians

of the future

Meet Bras DDP Fellows

We are proud that many former fellows hold leadership positions in academic Phase l clinical trials units. With this worldwide community of present, and former fellows collaborating in the area of early drug development, we have reason to believe that We Will Conquer Cancer in Our Lifetime!

BRAS DDP Fellows around the world

Aaron Hansen – Australia; Assistant Professor, Princess Margaret Cancer Centre, Toronto, CA
Alberto Ocana – Spain; Medical Director Translational Research Unit, Albacete University Hospital, Albacete, ES
Albiruni Razak – Malaysia; Assistant Professor, Princess Margaret Cancer Centre, Toronto, CA
Anastasios Stathis – Greece; Attending Physician Clinical Research Unit, Oncology Institute of Southern Switzerland, Bellinzona, CH
Anna Spreafico – Italy; Assistant Professor, Princess Margaret Cancer Centre, Toronto, CA
Arif Manji – Ontario, Canada; Assistant Professor, The Hospital for Sick Children, Toronto, CA
Ben Tran – Australia; Consultant Medical Oncologist, Royal Melbourne Hospital, Melbourne, AU
Benoit You – France; Head, Phase l Unit, Centre Hospitalier Lyon Sud, Lyon, FR
Bridgette Ma – Hong Kong; Director Phase l program, Princess of Wales Hospital, HK
Carol Townsley – Canada; Medical Director: After Cancer Treatment Transition Clinic, Women’s College Hospital, Toronto, CA
Christine Elser – Germany; Assistant Professor, Princess Margaret Cancer Centre, Toronto, CA
Christopohe Le Tourneau – France; Head, Phase l Unit, Institut Curie, Paris, FR
Cristina Martin-Lorente – Spain; Staff Medical Oncologist, Barcelona, ES
Daliah Tsoref – Israel; Staff Medical Oncologist, Davidoff Centre, IL
Daniel Renouf – British Columbia, Canada; Assistant Professor, B.C. Cancer Agency, Vancouver, CA
David Cescon – Ontario, Canada; Assistant Professor, Princess Margaret Cancer Centre, Toronto, CA
David Tan – Singapore; Consultant Medical Oncologist, National University Cancer Institute, SG
Donna Graham – Ireland; Clinical Research Fellow, Queen’s Belfast University, Northern Ireland, IE
Herbert Loong – Hong Kong; Assistant Professor, Princess of Wales Hospital, HK
Hui Gan – Australia; Head, Phase l Unit, Ludwig Institute of Cancer Research, Melbourne, AU
Ignacio Duran – Spain; GU Site Leader, Hospital Universitario Virgen del Rocio, Seville, ES
Irene Brana – Spain; Assistant Professor, Vali D’Hebron Hospital, Barcelona, ES
Ivan Diaz-Padilla – Spain; Sr. Medical Scientific Expert, Novartis Pharma AG, Basel, CH
Joanne Chiu – Hong Kong; Assistant Professor, University of Hong Kong, HK
Laura Vidal – Spain; Medical Director, INC Research
Linda Lee – Ontario, Canada; Assistant Professor, McMaster University – Niagara Campus, St. Catherines, CA
Mark Agulnik – Quebec, Canada; Associate Professor, Northwestern University, Chicago, US
Michelle Wilson – Melbourne; Staff Medical Oncologist, The University of Auckland, NZ
Natalie Cook – United Kingdom; Consultant Medical Oncologist, University of Manchester, Manchester, UK
Neda Stjepanovic – Serbia; Staff Medical Oncologist, Vall D’Hebron Hospital, Barcelona, ES
Neesha Dhani – Ontario, Canada; Assistant Professor, Princess Margaret Cancer Centre, Toronto, CA
Nicole Chau – Ontario, Canada; Instructor, Dana Farber Cancer Institute, Boston, US
Patricia Tang – Alberta, Canada; Associate Professor, Tom Baker Cancer Centre, Calgary, CA
Rossanna Pezo – United States; Staff Medical Oncologist, Sunnybrook Odetta Cancer Centre, Toronto, CA
Sara Taylor – Ontario, Canada; Assistant Professor, British Columbia Cancer Agency – Centre for Southern Interior, Kelowna, CA
Solmaz Sahebjam – Iran; Assistant Professor, H. Lee Moffitt Cancer Center, Tampa, US
Srikala Sridhar – Canada; Associate Professor, Princess Margaret Cancer Centre, Toronto, CA
Stephanie Lheureux – France; Assistant Professor, Princess Margaret Cancer Centre, Toronto, CA
Steven Welch – Ontario, Canada; Associate Professor, London Health Sciences Centre, London, CA
Tom (Wei-Wu) Chen – Taiwan; Assistant Professor, National Taiwan University Hospital, Taipei, TW
Victor Rodriguez-Freixinos – Spain; Staff Medical Oncologist, Vall D’Hebron Institute of Oncology, Barcelona, ES
Vincent Castonguay – Quebec, Canada; Assistant Professor, Laval University, Quebec City, CA

  • The experiences and the knowledge I have gained working at the Bras Drug Development Program has had a huge impact on me and will always stay with me. I hope to establish future collaborations with my colleagues and mentors here.

    Dr. Daphne DaiDr. Daphne DaiBRAS DDP Clinical Fellow – Australia
  • The Bras Drug Development Program is definitely unique in that it’s a well-oiled machine. It’s made up of a large number of individuals who each play an integral part. As a fellow, I’ve always felt well supported and I have the resources to be successful in my research. During my time here, I’ve been able to develop protocols and see them to fruition because of the resources at my disposal.

    Dr. Victoria MandilarasDr. Victoria MandilarasBRAS DDP Clinical Fellow – Montreal, Canada
  • The Princess Margaret Cancer Centre is a great place to learn and work. There are fellows and staff coming from all over the world. And there are good reasons for that. Our patients have access to the most up-to-date treatment programs and drug trials.

    Dr. Ilaria ColomboDr. Ilaria ColomboBRAS DDP Clinical Fellow – Italy
  • The most rewarding aspect of my medical career is my interactions with my patients. I think it is a true privilege that, as medical oncologists, we get to be there through what is most often the most difficult times in our patients’ and their families’ lives. My patients and their families have shown me how the human spirit can triumph through the most trying of times. This gives me the hope and encouragement that together, we will, and we have to, find ways to cure cancer.

    Dr. Amy PrawiraDr. Amy PrawiraBRAS DDP Clinical Fellow – Indonesia and Australia
  • The reason why I am here is, similar to the BRAS DDP, my hospital in Hong Kong have also newly established a Phase 1 Clinical Trials Unit. We shall be performing earlier phase drug testing and clinical trials for cancer patients. The BRAS DDP is a renowned unit in this field, and has a very high position globally. I am quite sure this is the most successful unit in Canada!

    Dr. Herbert LoongDr. Herbert LoongClinical Fellow at BRAS DDP – Hong Kong
  • The Princess Margaret Cancer Centre and the BRAS Drug Development Program, have gained international recognition, which has made it a great place to learn and grow.

    Dr. Anna SpreaficoDr. Anna SpreaficoBRAS DDP Clinical Fellow – Milan, Italy